Innovation Pharmaceuticals Inc (IPIX)

[Justfactsmam]

...for the fools that are scalping for pennies and don't believe the results of any of IPIX's phase 2 trials can move shares...I bring your attention to $SAGE$ results on ONLY a 89 subject PH2 trial with positive results...

UP $60 in pre-open!

This could be IPIX!!!

"123" keep your .017...lose your multiple dollars$$$$ on a IPIX reporting of significant trials results coming any day, any time.

Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket

Up over $60 this AM ...with more to come!

Dec. 7, 2017 7:18 AM ET|About: Sage Therapeutics (SAGE)|By: Douglas W. House, SA News Editor
Sage Therapeutics (NASDAQ:SAGE) is up 52% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.

The 89-subject study met its primary endpoint of a statistically significant average reduction in HAM-D score from baseline to day 15 (p<0.0001) versus placebo. HAM-D is a rating scale for depression. At day 15, 64% of patients in the treatment group achieved remission compared to 23% for placebo (p=0.0005). Other secondary endpoints were also met.

SAGE-217 was generally well-tolerated with no serious or severe adverse events observed. The most common adverse events were headache, dizziness, nausea and drowsiness.

Management will host a conference call this morning at 8:00 am ET to discuss the results.

SAGE-217, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function. The company intends to advance the program into Phase 3 development.